linjc16/ctgov huggingface dataset:
Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia

Study Overview
=================
Brief Summary
-----------------
Acute eosinophilic pneumonia (AEP) is diagnosed by cell count analysis of bronchoalveolar lavage fluid. However, the performance of bronchoscopy is not easy for patients with AEP, because they usually have hypoxia. Exhaled nitric oxide (FeNO) is usually elevated in the patients with eosinophilic inflammation such as asthma, but there is no previous studies FeNO in the patients with AEP. Investigators hypothesized that FeNO elevated significantly in patients with AEP, and FeNO can be used as non-invasive diagnostic method in patients who are clinically suspected with AEP, especially when the performance of bronchoscopy is difficult.

Official Title
-----------------
Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia

Conditions
-----------------
Acute, Eosinophilic Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who visited the study hospital with bilateral pneumonic infiltration. Exclusion Criteria: Patients who do not agree with our study protocol
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute eosinophilic pneumonia<br> | |
| Community acquired pneumonia<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The difference of FeNO in AEP and Community Acquired Pneumonia |  | Six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute eosinophilic pneumonia, Exhaled nitric oxide
Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

Study Overview
=================
Brief Summary
-----------------
Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.

Detailed Description
-----------------
Ptergyia are chronic fibrovascular lesions of the ocular surface. This study is designed to look for a signal of efficacy when the lesions are in a phase of active vascular growth. This phase is most often caught in a newly recurring pterygia post-operatively. Patients identified with actively growing lesions, will be offered local injections directly beneath the lesions. They will be examined for any adverse side effects and regression of the lesion.

Official Title
-----------------
The Use of Ranibizumab to Control Pterygium Growth in Recurrences and in Non-surgical Primary Lesions.

Conditions
-----------------
Pterygium

Intervention / Treatment
-----------------
* Drug: Ranibizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with actively growing pterygia, either surgical recurrences, or non-surgical primary lesions. Exclusion Criteria: Pregnancy History of CVA Monocular patients Minors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ranibizumab treatment<br>Patients will receive a sub-tenons injection of Ranibizumab 0.5mg, to be repeated twice with 30 day intervals between each dose. | Drug: Ranibizumab<br>* Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety | The following safety criteria will be monitored: subjective complaints, objective signs of inflammation, intraocular pressure, tear film and ocular surface integrity. | Within the first 30 days after injection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Regression of pterygium | Regression of the lesion will be determined by measurement if the horizontal extension of the lesion relative to the limbus, and by photographic comparison incorporating software analysis | Within 30 days after drug injection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pterygium
Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing hematopoietic stem cell transplantation (HSCT).

Detailed Description
-----------------
Occult hepatitis B virus (HBV) reactivation has been documented in bone marrow transplantation recipients who are hepatitis B surface antigen (HBsAg)-negative but with serologic evidence of prior exposure to HBV. However detailed prospective studies documenting the incidence of reactivation and the virologic and serologic kinetics of reactivation are lacking. The investigators prospective study proposes to follow-up 50 such bone marrow transplant recipients with all serologic and virologic parameters monitored every 4 weeks. Patients with detectable HBV DNA will be started on nucleoside analogue therapy. The optimal method and duration of monitoring will also be determined from our study.

Official Title
-----------------
Risk of Hepatitis B Reactivation After Hematopoietic Stem Cell Transplantation in Donors and Recipients With Prior HBV Exposure

Conditions
-----------------
Exposure to Hepatitis B Virus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented HBsAg-negative HSCT recipient with or without antibody to the hepatitis B surface antigen (anti-HBs). Documented anti-HBc (total)-positive. Exclusion Criteria: Concomitant liver diseases including chronic hepatitis C and D infection, Wilson's disease, autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. Significant alcohol intake (>30 grams per day)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HBsAg-negative, anti-HBc-positive<br>HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HBV reactivation (defined as detectable HBV DNA >20 IU/mL) | From date of hematopoietic stem cell transplantation (HSCT) to 2 years after HSCT. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hepatitis B, anti-HBc, HBsAg, HSCT, recipients
the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock

Study Overview
=================
Brief Summary
-----------------
the study is developed to evaluate the effect of use of oral vasopressors (midodrine versus minirin) on weaning ICU patients from IV vasopressors (noradrenaline) and compare between them for efficacy in shortage the duration of IV vasopressor and has low complications and side effects.

Official Title
-----------------
The Effect of Oral Midodrine Versus Oral Desmopressin Acetate Use for Liberation From IV Noradrenaline in Intensive Care Unit Patients Recovering From Spinal Shock .

Conditions
-----------------
Spinal Shock

Intervention / Treatment
-----------------
* Drug: Midodrine Oral Tablet
* Drug: Minirin oral tablet
* Drug: Nor-Adrenaline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 18 - 60 years. Patients of both genders. Patients diagnosed by spinal shock and they are in the recovery stage . Exclusion Criteria: Patient refusal. Anuric or oliguric patients or patients with chronic kidney disease. Patients with allergy to medication included in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: midodrine group<br>midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine | Drug: Midodrine Oral Tablet<br>* midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .<br>|
| Experimental: minirin group<br>the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin | Drug: Minirin oral tablet<br>* Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .<br>|
| Experimental: control group<br>the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin . | Drug: Nor-Adrenaline<br>* control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| liberation the patient from IV vasopressors with maintaining hemodynamics. | Blood pressure will be assessed regularly every 15 minutes | 48 hrs |
Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia

Study Overview
=================
Brief Summary
-----------------
Neuroapoptosis is induced by the administration of anesthetic agents to the young brain. Recent studies showed that the a2-adrenoceptor agonist, dexmedetomidine plays a trophic role during development and is neuroprotective in several settings of neuronal injury in animals. We hypothesized that neuroprotective effect of dexmedetomidine would be associated with evidence of brain injury detected by elevation of plasma concentration of glial fibrillary acid protein in children undergoing general anesthesia.

Detailed Description
-----------------
GFAP measure

Official Title
-----------------
The Effects of Dexmedetomidine on the Neurotoxicity From General Anesthesia Assessed by Plasma Glial Fibrillary Acidic Protein

Conditions
-----------------
Dexmedetomidine

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine Hydrochloride
* Other: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children undergoing general anesthesia longer than 3 hours Exclusion Criteria: past history of anesthesia cardiopulmonary bypass preexisting neurocognitive dysfunction abnormalities of liver profile (aspartate transaminase > 40 unit/L, alanine aminotransferase > 40 unit/L)

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dexmedetomidine<br>dexmedetomidine infusion | Drug: Dexmedetomidine Hydrochloride<br>* dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery<br>|
| Placebo Comparator: control<br>placebo infusion | Other: control<br>* 0.9% normal saline continuous infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glial fibrillary acid protein | plasma was collected at the given specific time | change from baseline glial fibrillary acid protein at 3 hours after the anesthetic induction |
Point of Care Ultrasound to Predict Intensive Care Unit Admission of Patients Presenting With Sepsis to the Emergency Department

Study Overview
=================
Brief Summary
-----------------
The FloPatch device will be applied to 150 septic patients in the emergency department before they receive fluid resuscitation. This study will assess whether initial FloPatch measured volume-responsiveness and volume of fluids used will predict a composite outcome of mortality, intensive care unit admission, or rapid response team activation. The development of fluid unresponsiveness throughout the initial fluid resuscitation will be assessed and its association with the composite outcome will be assessed.

Official Title
-----------------
The Use of Point of Care Ultrasound to Predict Intensive Care Unit Admission of Patients Presenting With Sepsis to the Emergency Department

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Emergency department patient 18+ years old Systolic blood pressure less than 100mmHg Respiratory rate greater than 22 breaths per minutes Temperature greater than 38 degrees Celsius or less than 36 degrees Celsius Heart rate greater than 90 beats per minute Exclusion Criteria: Already intubated prior to emergency department arrival Ventilator-dependent Patients transferred from another hospital Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mortality, ICU admission, or rapid response team activation<br>Carotid flow patterns and velocity time integral values, as determined by FloPatch. | |
| No mortality, ICU admission, or rapid response team activation<br>Carotid flow patterns and velocity time integral values, as determined by FloPatch. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | This study will ascertain whether the patient died within 24 hours of ED arrival. | 24 hours | 
| ICU admission | This study will ascertain whether the patient was admitted to the ICU within 24 hours of ED arrival. | 24 hours | 
| Rapid response team activation | This study will ascertain whether a rapid response team was activated for the patient within 24 hours of ED arrival. | 24 hours |
Protein Requirements in Endurance-trained Athlete

Study Overview
=================
Brief Summary
-----------------
Protein requirements in individuals who participate in endurance-based exercise training have been suggested to be greater than the current recommended dietary allowance (RDA). Nutritional requirements for dietary amino acids in adults have traditionally been determined utilizing the nitrogen balance technique, which is prone to underestimating protein requirements. As a result, there is a need to re-evaluate recommendations in order to characterize how dietary amino acid needs may be modulated by physical activity. Recent studies using the minimally invasive indicator amino acid oxidation (IAAO) technique have suggested that protein requirements in young men are at least 50% higher than RDA based on nitrogen balance data. Therefore, the purpose of this study is to measure the protein requirement in endurance trained adults using the IAAO technique.

Official Title
-----------------
Evaluation of Protein Requirements in Male Endurance Athletes

Conditions
-----------------
Increased Metabolic Requirement, Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: amino acids intake


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, male, endurance-trained participants who regularly more than 40 km/week Ability to perform the exercise stimulus (20 km run) on metabolic trial. Exclusion Criteria: Inability to meet health and physical activity guidelines according to the physical activity readiness questionnaire (PAR-Q+) Inability to adhere to any of the protocol guidelines (i.e. alcohol, caffeine consumption) Regular tobacco use Illicit drug use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Endurance trained<br>subjects will receive different levels of amino acids intakes varying from 0.2 to 2.8 g/kg/day. | Dietary Supplement: amino acids intake<br>* amino acids intakes will be varied at 0.2-2.8 g/kg/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 13CO2 (carbon dioxide) excretion (μmol/kg/h) |  | 4 hours / study day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| [13C]phenylalanine oxidation (μmol/kg/h) |  | 4 hours/study day |
Probiotic Sport Study

Study Overview
=================
Brief Summary
-----------------
We investigate the impact of a probiotic-based dietary supplement on oxidative stress and endotoxemia before and after strenuous exercise. Hypotheses (H1): Supplementation has an influence on oxidative stress parameters before and post exercise Supplementation has an influence on parameters of endotoxemia and inflammation before and post exercise Strenuous exercise has an influence on parameters of oxidative stress, inflammation and endotoxemia

Official Title
-----------------
Impact of Supplementation With Probiotics on Exercise-induced Oxidative Stress and Endotoxemia in Trained Men

Conditions
-----------------
Oxidative Stress, Inflammation, Endotoxemia

Intervention / Treatment
-----------------
* Dietary Supplement: probiotic-based dietary supplement
* Dietary Supplement: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: trained men 30 - 45 years non-smokers 4wk wash out of all dietary supplements Exclusion Criteria: untrained people (VO2max < 55 ml x kg-1) female all people not matching this age group smokers all men taking dietary supplements all men that fail in ergometric exercise eligibility testing, refering to the standards in sports medicine (e.g.: significant ST-decrease or increase, blood pressure > 240 mmHg, tachycardia, polymorphic extrasystolia, cyanosis, bradyarrhythmia..) all people that are not adjudged as Healthy

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: probiotic-based dietary supplement<br> | Dietary Supplement: probiotic-based dietary supplement<br>* 24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day<br>* Other names: active group;|
| Placebo Comparator: placebo<br> | Dietary Supplement: placebo<br>* 24 trained men receive a placebo for 16 weeks with same dosage compared to active group<br>* Other names: passive group;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| markers of oxidative stress, endotoxemia and inflammation |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oxidative stress, inflammation, endotoxemia, strenuous exercise